CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving... (mproving lives. CSL Behring continu...)

CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies

Date:4/3/2008

mproving lives."

"CSL Behring continues to grow and expand its capacity to develop, manufacture, and supply a broad array of therapies around the world," said Paul Perreault, Executive Vice President of CSL Behring Worldwide Commercial Operations. "Canada is an extremely important market for us, and we look forward to delivering to Canadians the safe, effective, high-quality medicines for which our company has become known."

"One of Canadian Blood Services strategic directions for plasma protein products is to broaden its supplier base for commercial products and fractionation services," said Dr. Graham Sher, Chief Executive Officer of Canadian Blood Services. "This new partnership with CSL allows us to successfully achieve this strategic objective."

"With its long history of success in the biotherapies industry, CSL Behring Canada has shown it can perform as a trustworthy partner," said Dr. Francine Decary, President and CEO of Hema-Quebec. "We look forward to initiating what we expect to be a long and productive business relationship with CSL Behring in the supply of important medicines to patients in Quebec."

About Hemophilia A and von Willebrand Disease

Hemophilia is a bleeding disorder caused by a deficiency in one of the blood clotting factors (Factor VIII). Hemophilia A (often called classic hemophilia) accounts for about 80% of all hemophilia cases.

Hemophilia A is a hereditary disorder in which the clotting ability of the blood is impaired and excessive bleeding results. Small wounds and punctures are usually not a problem, but uncontrolled internal bleeding can result in pain and swelling as well as permanent damage, especially to joints and muscles.

The severity of symptoms can vary between individuals and the most severe forms become apparent early on during a child's development. Prolonged bleeding is the hallmark of hemophilia A and is typically first noticed when an infant is circumcised. Additional ble
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. CSL Behring Expands Into Middle East Market with Haemate(R) P
2. Siemens Completes Acquisition of Dade Behring
3. Siemens Receives EU Antitrust Clearance for Acquisition of Dade Behring
4. AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian Countries
5. Pharsight Signs Two New DMX(R) License Customers
6. Siemens Signs Multi-Year Agreement With Cleveland Clinic to Deploy Enterprise-Wide Cardiology PACS
7. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany
8. Cardiac Science Signs Letter of Intent With Misys Healthcare Systems to Connect With Their EMR Systems
9. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France
10. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
11. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia

Post Your Comments:

CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving...(mproving lives. CSL Behring continu...)